Cosmax (A192820) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
20 Feb, 2026Executive summary
Q3 2024 saw consolidated sales rise 15.6% year-over-year to KRW 529.8 bn, with strong growth in Korea and Southeast Asia offsetting declines in China and the US.
Operating profit increased 30.4% year-over-year to KRW 43.4 bn, and net profit surged 90.9% to KRW 20.6 bn.
Korea led growth with a 20.8% sales increase and 52.7% rise in operating profit, while Southeast Asia posted robust gains; China and US subsidiaries remained sluggish.
Financial highlights
Revenue reached KRW 529.8 bn, up 15.6% year-over-year; gross profit rose 24.8% to KRW 97.6 bn.
Operating profit margin improved to 8.2%, driven by cost controls and reduced bad debt expense.
Net profit nearly doubled to KRW 20.6 bn, despite a non-operating loss of KRW 20.8 bn from interest and exchange losses.
Equity increased to KRW 475.5 bn, with retained earnings at KRW 381.1 bn.
Outlook and guidance
Continued solid demand expected in Korea and Southeast Asia, with focus on indie brands and operational efficiency.
China and US outlook remains cautious due to ongoing recessionary pressures and delayed customer inflows.
Latest events from Cosmax
- Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Q2 2024 delivered double-digit sales and profit growth, driven by Korea and Southeast Asia.A192820
Q2 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026 - Revenue and operating profit grew, but net profit dropped due to one-off and non-operating losses.A192820
Q1 202520 Feb 2026 - Revenue up 1.0% YoY, but net loss widened on one-off costs; BTI outperformed.A192820
Q3 202520 Feb 2026 - Record revenue and profit growth offset by net profit decline from non-operating expenses.A192820
Q2 202512 Aug 2025